Published in:
01-02-2012 | Original Article
Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany
Authors:
Lewin Eisele, Jan Dürig, Andreas Hüttmann, Ulrich Dührsen, Roland Assert, Beate Bokhof, Raimund Erbel, Klaus Mann, Karl-Heinz Jöckel, Susanne Moebus, on behalf of the Heinz Nixdorf Recall Study Investigative Group
Published in:
Annals of Hematology
|
Issue 2/2012
Login to get access
Abstract
We determined the prevalence and progression rate of monoclonal gammopathy of undetermined significance (MGUS) and light-chain MGUS (LCMGUS) in Germany utilizing the biobank of the population-based Heinz Nixdorf Recall Study. The Heinz Nixdorf Recall Study comprises 4,814 men and women aged 45–75 years. To detect monoclonal proteins, standard serum electrophoresis was combined with parallel screening immunofixation using pentavalent antisera. Additionally, free light chains (FLC) were measured in all samples. Definition of MGUS included M-protein concentration, laboratory results, and disease history. LCMGUS was defined as abnormal FLC ratio, increase in FLC causing the abnormal ratio, and lack of intact immunoglobulin. One hundred sixty-five MGUS cases were identified among 4,702 screened samples (prevalence 3.5%, 95% confidence interval (CI) 3.0–4.1; median age 63 years, range 47–75 years; 103 (62%) male; IgG 59%, IgA 17%, IgM 17%, biclonal 4.8%, kappa 56%, and lambda 44%). Five cases progressed (0.6%/year, 95% CI 0.2–1.4). An abnormal FLC ratio was detected in 220 samples. Thirty-nine of these showed intact immunoglobulin. Thirty-four of the remaining met LCMGUS criteria (prevalence 0.7%, 95% CI 0.5–1.0). None of the LCMGUS cases progressed. We demonstrate a MGUS prevalence of 3.5% and a LCMGUS prevalence of 0.7% in the general population aged 45–75 years in Germany using a sensitive screening approach.